key: cord-0257775-fr3tz1do
authors: Nomura, Y.; Sawahata, M.; Nakamura, Y.; Kurihara, M.; Koike, R.; Katsube, O.; Hagiwara, K.; Niho, S.; Masuda, N.; Tanaka, T.; Sugiyama, K.
title: Age and smoking predict antibody titres at 3 months after the second dose of the BNT162b2 COVID-19 vaccine
date: 2021-08-07
journal: nan
DOI: 10.1101/2021.08.06.21261590
sha: b404e7cf6d439901525fab93b7423944f5e299d8
doc_id: 257775
cord_uid: fr3tz1do

Objective: We aimed to determine antibody (Ab) titres 3 months after the second dose of the BNT162b2 coronavirus disease-2019 (COVID-19) vaccine and to explore clinical variables predicting these titres in Japan. Methods: We enrolled 378 healthcare workers (255 women, 123 men) whose blood samples were collected 91 plus or minus 15 days after the second of two inoculations of the BNT162b2 COVID-19 mRNA vaccine (Pfizer/BioNTech) given 3 weeks apart. Medical histories and demographic characteristics were recorded using a structured self-reported questionnaire. The relationships between Ab titres and these factors were analysed. Results: Median age (interquartile range [IQR]) of the participants was 44 (32-54) years. Median Ab titre (IQR) against the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) spike antigen was 764 (423-1140) U/mL. Older participants had significantly lower Ab titres; median (IQR) Ab titres were 942 (675-1390) and 1095 (741-1613) U/mL in men and women in their 20s, respectively, but 490 (297-571) and 519 (285-761) U/mL in men and women in their 60s-70s, respectively. In the age-adjusted analysis, the only risk factors for lower Ab titres were male sex and smoking. However, the sex difference may have arisen from the sex difference in smoking rate. Moreover, Ab titres were significantly lower in current smokers than in ex-smokers. Conclusion: The most important factors associated with low Ab titres were age and smoking habit. In particular, current smoking status caused lower Ab titres, and smoking cessation before vaccination may improve the individual efficacy of the BNT162b2 vaccine.

In Japan, the BNT162b2 vaccine (Pfizer/BioNTech) was selected as the first coronavirus disease-2019 (COVID-19) mRNA vaccine to be administered to healthcare professionals, starting in February 2021. Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has an enveloped, single, positive-stranded RNA genome that encodes four major viral structural proteins, namely nucleocapsid (N), spike (S), envelope (E) and membrane (M) proteins; the latter three proteins are found in its membrane. The spike protein guides viral entry into host cells [1] by binding to ACE2 (angiotensin-converting enzyme 2), the main virus receptor, which is widely expressed on epithelial cells and macrophages [1] [2] [3] and is thus an ideal target for mRNA vaccine development [3] .

Because efficacy in clinical trials and effectiveness in the community depend on the proportions of SARS-CoV-2 variants spreading in a given area, immunogenicity has attracted increasing attention as an individual index for the efficacy of COVID-19 mRNA vaccines.

Humoral immunity plays major roles in protecting against and surviving SARS-CoV-2 infection [4, 5] , and neutralising antibodies (Abs) are correlated with protection against several viruses, including SARS-CoV-2 [6] [7] [8] [9] . However, few studies have investigated real-world Ab titres following vaccination with BNT162b2; instead, focus has been placed on the Ab status shortly after vaccination, which can provide vital information for predicting long-term effectiveness [10] [11] [12] . A few studies have investigated the associations between Ab titres and individual demographic, medical, and lifestyle factors [13] ; these studies focused on short-term Ab titre data and demonstrated that lower Ab titres were associated with older age [10] [11] [12] . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted August 7, 2021. ; https://doi.org/10.1101/2021.08.06.21261590 doi: medRxiv preprint Ab titres against the SARS-CoV-2 spike antigen produced in response to this mRNA vaccine in the Japanese population. Our results showed that the average peak titre of 2031.7±692.0 U/mL in 6 healthcare workers in their 50s and 60s had markedly decreased to 513.3±261.7 U/mL by 15 weeks after the second inoculation. Here, we aimed to determine Ab titres against the SARS-CoV-2 spike antigen 3 months after the second dose of the BNT162b2 vaccine in 378 healthcare workers and to explore the factors associated with these Ab titres across a comprehensive range of clinical and lifestyle characteristics in Japan.

. CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review)

The copyright holder for this preprint this version posted August 7, 2021. ;

In this single-centre prospective observational study, we recruited healthcare workers whose blood samples were collected 91±15 days after the second of two BNT162b2 vaccine inoculations (Pfizer/BioNTech) administered 3 weeks apart in February-March 2021 in National Hospital Organization Utsunomiya National Hospital in Tochigi prefecture, Japan.

Initially, 381 participants were recruited, but we excluded 1 participant who received only the first dose of the BNT162b2 vaccine and 2 participants whose blood sampling confirmed the presence of Abs against SARS-CoV-2 (nucleoproteins) prior to vaccination.

Finally, we enrolled 378 healthcare workers (255 women, 123 men), including the 6 from our preliminary study [18] , and their medical histories and demographic characteristics were recorded using a structured self-reported questionnaire.

Blood samples collected 91±15 days after the second inoculation were used to measure total Ab titres against the SARS-CoV-2 spike antigen, using a commercially available electrochemiluminescence immunoassay (ECLIA) (Elecsys® Anti-SARS-CoV-2 RUO; Roche Diagnostics) [19] . The relationships between Ab titres against the SARS-CoV-2 spike antigen and clinical and lifestyle characteristics were analysed. This study was approved by the Ethics Committee of National Hospital Organization Utsunomiya National Hospital (No. 03-01, April 19, 2021). Written informed consent was obtained from all study participants before enrolment.

Nonparametric continuous data are expressed as the median with interquartile range (IQR). Categorical data are presented as absolute numbers and relative frequencies (n, %). To . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review)

The copyright holder for this preprint this version posted August 7, 2021. . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review)

The copyright holder for this preprint this version posted August 7, 2021. ; https://doi.org/10.1101/2021.08.06.21261590 doi: medRxiv preprint

In total, 378 healthcare workers (255 women, 123 men) were enrolled in this study.

Their baseline characteristics are summarised in Table 1 (613-1410), 827 (501-1150), 685 (377-1035) and 519 (285-761) U/mL, respectively. Men in each age group tended to have lower median Ab titres than women in the same age group, although the differences were not significant (Figure 2) .

We first performed univariate analyses to identify factors associated with serum Ab titres against the SARS-CoV-2 spike protein. The factors significantly associated with a lower Ab titre were older age, male sex, smoking, skin allergy (including atopic dermatitis), . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review)

The copyright holder for this preprint this version posted August 7, 2021. ;  diabetes mellitus and hypertension ( Table 1) .

We also analysed the risk factors for lower Ab titres after adjustment for age, because the prevalence of the factors may differ according to age, such as hypertension. In the age-adjusted analysis, individual Ab titres were recalculated by means of subtraction of the median Ab titres according to corresponding age groups. Median Ab titres of participants in their 20s, 30s, 40s, 50s and 60s-70s were 1050, 931, 779, 619 and 491 U/mL, respectively.

For example, an age-adjusted Ab titre in 20s was calculated as follows; 'an individual Ab titre -1050'. After age adjustment, the only factors significantly associated with lower Ab titres were male sex and smoking ( Table 2 ). In terms of smoking, age-adjusted median Ab titres (IQR) were -174 (-378 to 145) and 90 (-174 to 512) in ever smokers and never smokers, respectively.

To analyse the observed sex difference, we divided the participants into ever smokers and never smokers. In both the male and female groups, age-adjusted median Ab titres were significantly lower in ever smokers than in never smokers; age-adjusted median Ab titres (IQR) in men were -246 (-398 to 65) and 49 (-186 to 621) in ever smokers and never smokers, respectively, while those in women were -140 (-304 to 217) and 95 (-151 to 503) in ever smokers and never smokers, respectively. However, in both the ever smoker and never smoker groups, no significant sex differences in age-adjusted median Ab titres were observed ( Table 3 ). Given that the smoking rates in the male and female groups were 61.0% and 31.0%, respectively, these results suggest that the sex difference in Ab titres strongly reflects sex differences in smoking, rather than biological sex differences. In addition, Ab titres were significantly lower in current smokers than in ex-smokers ( Table 4 ). These results suggest that smoking cessation will reduce the risk of a lower Ab titre.

. CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted August 7, 2021. ; 1 0

To our knowledge, this is the first study to report real-world Ab titres against the SARS-CoV-2 spike antigen at 3 months after vaccination and to identify the factors associated with these Ab titres across a comprehensive range of clinical and lifestyle characteristics in Japan. Three important findings were obtained. was the most impactful factor, and the sex difference in Ab titres was at least partly due to smoking. To clarify the effects of smoking, we performed additional analyses. However, the Brinkman Index and the number of cigarettes per day did not influence the Ab titres. Thus, smoking itself is a risk factor for low Ab titres, rather than the duration of smoking or number of cigarettes per day. Moreover, smoking cessation can be expected to effectively increase Ab titres because they were significantly lower in current smokers than in ex-smokers. On the other hand, another study reported that alcohol was the most impactful lifestyle factor, not smoking [10] . Although the authors of that study do not show age-adjusted data, their conclusions were different from ours. Their results were based on analysis of samples collected 2-5 weeks after the second dose of the vaccine. In contrast, our samples were obtained 3 months after the second dose. One hypothesis is that alcohol may affect Ab production, whereas smoking may lead to decreases in the level of Abs after they are produced. In addition, we believe that an age-adjusted analysis is critical. To clarify the reason for the difference between that study and ours, we need to analyse longitudinal data to observe changes in Ab titres over time, and we are planning such an additional study.

Some limitations and possible sources of bias in this study include the following.

First, the participants were limited in number and were all healthcare workers vaccinated at a single national hospital in Tochigi prefecture, where the COVID-19 pandemic has been . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted August 7, 2021. ; 1 3 well-controlled since SARS-CoV-2 began spreading around the globe. Therefore, the results obtained in this study might not be generalisable on a wide scale, or even within Japan.

Second, several data, including body height and weight, were obtained by means of a standardised structured self-reported questionnaire. We cannot deny the possibility that some data may have been affected by recall bias. Third, the cut-off level of the Ab against the SARS-CoV-2 spike antigen needs to be determined for the different variants of SARS-CoV-2, but this information is currently unavailable. Further studies are needed to confirm our observations.

In conclusion, we have reported for the first time real-world Ab titres against the SARS-CoV-2 spike antigen at 3 months after the second dose of the BNT162b2 vaccine, which were much lower than those measured shortly after the second inoculation. We demonstrated that the most important factors associated with low Ab titres were age and smoking habit. In particular, current smoking status causes lower Ab titres, and smoking cessation before vaccination may improve the individual effectiveness of the BNT162b2 vaccine. To establish a more personalised approach to vaccination involving earlier boosters, different schedules or different types of vaccines, further studies are necessary regarding the associations between Ab titres and the comprehensive medical histories of individuals.

. CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted August 7, 2021. ; 1 4

The authors thank all staff in National Hospital Organization Utsunomiya National Hospital for supporting sample collection. We would like to thank Ms. Miwa Okada, Ms. Junko Shibayama, Ms. Yuko Tajima, Ms. Mami Ochiai, Ms. Midori Takahashi, Ms. Hiroko Ueno, Ms. Natsuka Suzuki, and Ms. Yoshino Iwaya for supporting data analysis.

The authors declare no conflict of interest.

. CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted August 7, 2021. is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted August 7, 2021. is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted August 7, 2021. is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted August 7, 2021. . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review)

The copyright holder for this preprint this version posted August 7, 2021. ; https://doi.org/10.1101/2021.08.06.21261590 doi: medRxiv preprint Table 4 . Age-adjusted median antibody titres in ever smokers: current smokers vs ex-smokers Antibody . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review)

The copyright holder for this preprint this version posted August 7, 2021. ; . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review)

The copyright holder for this preprint this version posted August 7, 2021. ;

Antibody titres in both men and women tended to decrease as participants' age increased from their 20s to 70s. Median (IQR) antibody titres of men in their 20s, 30s, 40s, 50s and 60s-70s were 942, 821, 710, 449 and 490 U/mL, respectively. Median (IQR) antibody titres of women in their 20s, 30s, 40s, 50s and 60s-70s were 1095, 991, 827, 685 and 519 U/mL, respectively. Men in each age group tended to have lower median antibody titres than women in the same age group. *p < 0.05, **p < 0.01.

. CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review)

The copyright holder for this preprint this version posted August 7, 2021. ;

From SARS to MERS, Thrusting Coronaviruses into the Spotlight

SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor

Receptor-binding domains of spike proteins of emerging or re-emerging viruses as targets for development of antiviral vaccines

Neutralizing antibody responses to SARSCoV-2 in symptomatic COVID-19 is persistent and critical for survival

Antibody Status and Incidence of SARS-CoV-2 Infection in Health Care Workers

Rapid detection of neutralizing antibodies to SARS-CoV-2 variants in post-vaccination sera. medRxiv

Correlates of protection induced by vaccination

Age-adjusted median antibody titres in ever smokers vs never smokers Male, Antibody, median (IQR) Female

IQR) P-value between sexes Ever smokers (men, 75; women, 79) −246 (−398 to 65) −140 (−304 to 217) 0.1175 * Never smokers (men, 48